Logo image of CYTK

CYTOKINETICS INC (CYTK) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:CYTK - US23282W6057 - Common Stock

65.67 USD
-0.87 (-1.31%)
Last: 12/5/2025, 8:12:30 PM
65.67 USD
0 (0%)
After Hours: 12/5/2025, 8:12:30 PM
Fundamental Rating

2

CYTK gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. Both the profitability and financial health of CYTK have multiple concerns. CYTK is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

CYTK had negative earnings in the past year.
CYTK had a negative operating cash flow in the past year.
CYTK had negative earnings in each of the past 5 years.
CYTK had negative operating cash flow in 4 of the past 5 years.
CYTK Yearly Net Income VS EBIT VS OCF VS FCFCYTK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200M -400M

1.2 Ratios

CYTK has a Return On Assets (-52.34%) which is in line with its industry peers.
Industry RankSector Rank
ROA -52.34%
ROE N/A
ROIC N/A
ROA(3y)-48.08%
ROA(5y)-38.73%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CYTK Yearly ROA, ROE, ROICCYTK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K

1.3 Margins

CYTK does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CYTK Yearly Profit, Operating, Gross MarginsCYTK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

More info and screens

3

2. Health

2.1 Basic Checks

CYTK does not have a ROIC to compare to the WACC, probably because it is not profitable.
CYTK has more shares outstanding than it did 1 year ago.
The number of shares outstanding for CYTK has been increased compared to 5 years ago.
The debt/assets ratio for CYTK has been reduced compared to a year ago.
CYTK Yearly Shares OutstandingCYTK Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
CYTK Yearly Total Debt VS Total AssetsCYTK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B

2.2 Solvency

Based on the Altman-Z score of -1.28, we must say that CYTK is in the distress zone and has some risk of bankruptcy.
CYTK's Altman-Z score of -1.28 is in line compared to the rest of the industry. CYTK outperforms 54.49% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -1.28
ROIC/WACCN/A
WACC8.46%
CYTK Yearly LT Debt VS Equity VS FCFCYTK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M 600M

2.3 Liquidity

A Current Ratio of 6.88 indicates that CYTK has no problem at all paying its short term obligations.
With a decent Current ratio value of 6.88, CYTK is doing good in the industry, outperforming 69.85% of the companies in the same industry.
A Quick Ratio of 6.88 indicates that CYTK has no problem at all paying its short term obligations.
CYTK has a better Quick ratio (6.88) than 70.04% of its industry peers.
Industry RankSector Rank
Current Ratio 6.88
Quick Ratio 6.88
CYTK Yearly Current Assets VS Current LiabilitesCYTK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

5

3. Growth

3.1 Past

CYTK shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -17.47%.
Looking at the last year, CYTK shows a very strong growth in Revenue. The Revenue has grown by 2609.26%.
The Revenue has been decreasing by -7.24% on average over the past years.
EPS 1Y (TTM)-17.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-87.5%
Revenue 1Y (TTM)2609.26%
Revenue growth 3Y-35.98%
Revenue growth 5Y-7.24%
Sales Q2Q%318.14%

3.2 Future

The Earnings Per Share is expected to grow by 15.64% on average over the next years. This is quite good.
The Revenue is expected to grow by 237.61% on average over the next years. This is a very strong growth
EPS Next Y-8.98%
EPS Next 2Y-4.9%
EPS Next 3Y9.27%
EPS Next 5Y15.64%
Revenue Next Year2503.25%
Revenue Next 2Y554.05%
Revenue Next 3Y389.93%
Revenue Next 5Y237.61%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CYTK Yearly Revenue VS EstimatesCYTK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1B 2B 3B
CYTK Yearly EPS VS EstimatesCYTK Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 -5 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CYTK. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CYTK. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CYTK Price Earnings VS Forward Price EarningsCYTK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CYTK Per share dataCYTK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-4.9%
EPS Next 3Y9.27%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CYTK!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CYTOKINETICS INC

NASDAQ:CYTK (12/5/2025, 8:12:30 PM)

After market: 65.67 0 (0%)

65.67

-0.87 (-1.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05 2025-11-05/amc
Earnings (Next)02-25 2026-02-25/amc
Inst Owners116.32%
Inst Owner Change6.9%
Ins Owners0.45%
Ins Owner Change-0.14%
Market Cap8.03B
Revenue(TTM)87.21M
Net Income(TTM)-751.92M
Analysts80
Price Target80.01 (21.84%)
Short Float %11.98%
Short Ratio7.63
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-18.98%
Min EPS beat(2)-58.24%
Max EPS beat(2)20.28%
EPS beat(4)2
Avg EPS beat(4)-10.04%
Min EPS beat(4)-58.24%
Max EPS beat(4)20.28%
EPS beat(8)2
Avg EPS beat(8)-15.27%
EPS beat(12)2
Avg EPS beat(12)-20.48%
EPS beat(16)4
Avg EPS beat(16)-8.95%
Revenue beat(2)1
Avg Revenue beat(2)1299.97%
Min Revenue beat(2)-46.62%
Max Revenue beat(2)2646.57%
Revenue beat(4)3
Avg Revenue beat(4)870.43%
Min Revenue beat(4)-46.62%
Max Revenue beat(4)2646.57%
Revenue beat(8)3
Avg Revenue beat(8)406.55%
Revenue beat(12)4
Avg Revenue beat(12)259.37%
Revenue beat(16)6
Avg Revenue beat(16)381.31%
PT rev (1m)3.38%
PT rev (3m)9.03%
EPS NQ rev (1m)10.01%
EPS NQ rev (3m)7.94%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.66%
Revenue NQ rev (1m)8.87%
Revenue NQ rev (3m)-17.27%
Revenue NY rev (1m)0%
Revenue NY rev (3m)7.58%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 92.06
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-6.32
EYN/A
EPS(NY)-5.79
Fwd EYN/A
FCF(TTM)-3.71
FCFYN/A
OCF(TTM)-3.54
OCFYN/A
SpS0.71
BVpS-4.26
TBVpS-4.26
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -52.34%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-48.08%
ROA(5y)-38.73%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 212.08%
Cap/Sales 23.45%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.88
Quick Ratio 6.88
Altman-Z -1.28
F-Score3
WACC8.46%
ROIC/WACCN/A
Cap/Depr(3y)82.69%
Cap/Depr(5y)599.06%
Cap/Sales(3y)17.31%
Cap/Sales(5y)28.23%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-17.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-87.5%
EPS Next Y-8.98%
EPS Next 2Y-4.9%
EPS Next 3Y9.27%
EPS Next 5Y15.64%
Revenue 1Y (TTM)2609.26%
Revenue growth 3Y-35.98%
Revenue growth 5Y-7.24%
Sales Q2Q%318.14%
Revenue Next Year2503.25%
Revenue Next 2Y554.05%
Revenue Next 3Y389.93%
Revenue Next 5Y237.61%
EBIT growth 1Y-9.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-15.12%
EBIT Next 3Y3.51%
EBIT Next 5Y24.98%
FCF growth 1Y-2.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y1.17%
OCF growth 3YN/A
OCF growth 5YN/A

CYTOKINETICS INC / CYTK FAQ

What is the fundamental rating for CYTK stock?

ChartMill assigns a fundamental rating of 2 / 10 to CYTK.


What is the valuation status of CYTOKINETICS INC (CYTK) stock?

ChartMill assigns a valuation rating of 0 / 10 to CYTOKINETICS INC (CYTK). This can be considered as Overvalued.


Can you provide the profitability details for CYTOKINETICS INC?

CYTOKINETICS INC (CYTK) has a profitability rating of 0 / 10.


Can you provide the financial health for CYTK stock?

The financial health rating of CYTOKINETICS INC (CYTK) is 3 / 10.